Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age - sprookjes - yvandenbroek - TriplyDB

Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age

Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age

http://www.wikidata.org/entity/Q24658073

about

Vaccines against malaria Advances and challenges in malaria vaccine development Immune mechanisms in malaria: new insights in vaccine development Vaccine-induced monoclonal antibodies targeting circumsporozoite protein prevent Plasmodium falciparum infection The impact of malaria parasitism: from corpuscles to communities Structure of the Plasmodium falciparum circumsporozoite protein, a leading malaria vaccine candidate Hemoglobinopathies: slicing the Gordian knot of Plasmodium falciparum malaria pathogenesis Vaccine Adjuvants: from 1920 to 2015 and Beyond Successful vaccines for naturally occurring protozoal diseases of animals should guide human vaccine research. A review of protozoal vaccines and their designs Targeting Plasmodium falciparum Hsp90: Towards Reversing Antimalarial Resistance Malaria vaccine: a future hope to curtail the global malaria burden Vaccines for the 21st century Vaccines for malaria: how close are we?Acyclic Immucillin Phosphonates: Second-Generation Inhibitors of Plasmodium falciparum Hypoxanthine- Guanine-Xanthine Phosphoribosyltransferase Young lives lost as B cells falter: what we are learning about antibody responses in malaria.Reducing Plasmodium falciparum malaria transmission in Africa: a model-based evaluation of intervention strategies The US Food and Drug Administration provides a pathway for licensing vaccines for global diseases Immunogenicity of self-associated aggregates and chemically cross-linked conjugates of the 42 kDa Plasmodium falciparum merozoite surface protein-1 Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites The role of age and exposure to Plasmodium falciparum in the rate of acquisition of naturally acquired immunity: a randomized controlled trial Ensemble modeling of the likely public health impact of a pre-erythrocytic malaria vaccine T cell responses to the RTS,S/AS01(E) and RTS,S/AS02(D) malaria candidate vaccines administered according to different schedules to Ghanaian children Vaccine platforms combining circumsporozoite protein and potent immune modulators, rEA or EAT-2, paradoxically result in opposing immune responses Age-dependent maturation of Toll-like receptor-mediated cytokine responses in Gambian infants Induction of Plasmodium falciparum-specific CD4+ T cells and memory B cells in Gabonese children vaccinated with RTS,S/AS01(E) and RTS,S/AS02(D)Decreasing incidence of severe malaria and community-acquired bacteraemia among hospitalized children in Muheza, north-eastern Tanzania, 2006-2010 Serological evidence of discrete spatial clusters of Plasmodium falciparum parasites Circumsporozoite-specific T cell responses in children vaccinated with RTS,S/AS01E and protection against P falciparum clinical malaria Safety of the malaria vaccine candidate, RTS,S/AS01E in 5 to 17 month old Kenyan and Tanzanian Children Genetic linkage of autologous T cell epitopes in a chimeric recombinant construct improves anti-parasite and anti-disease protective effect of a malaria vaccine candidate Safety, immunogenicity and duration of protection of the RTS,S/AS02(D) malaria vaccine: one year follow-up of a randomized controlled phase I/IIb trial High antibody titer against apical membrane antigen-1 is required to protect against malaria in the Aotus model Acquired antibody responses against Plasmodium vivax infection vary with host genotype for duffy antigen receptor for chemokines (DARC)Vaccines, new opportunities for a new society.Sustainable development of a GCP-compliant clinical trials platform in Africa: the malaria clinical trials alliance perspective.Reliable enumeration of malaria parasites in thick blood films using digital image analysis.Efficacy of RTS,S malaria vaccines: individual-participant pooled analysis of phase 2 data.Peripheral blood monocyte-to-lymphocyte ratio at study enrollment predicts efficacy of the RTS,S malaria vaccine: analysis of pooled phase II clinical trial data.Relationship between child survival and malaria transmission: an analysis of the malaria transmission intensity and mortality burden across Africa (MTIMBA) project data in Rufiji demographic surveillance system, Tanzania.Impact of RTS,S/AS02(A) and RTS,S/AS01(B) on genotypes of P. falciparum in adults participating in a malaria vaccine clinical trial.

P2860

Q17485685-C2170908-7997-4811-8356-7FB8DA344028 Q21032463-958B4DE8-2F01-447E-BD8E-3A4D812CFD92 Q21032484-820F7B45-7413-4B02-A6E5-5F8E52D7E799 Q24628167-8C59B0A1-615F-4FE5-872C-FDFA754AFEDA Q24644343-9F0D0AD2-E021-4650-9677-DECC12218165 Q24648408-CB6FC562-B166-48A6-BB50-81426AA3072D Q24810377-D83C83B0-A1A2-47D9-A670-DC1E92358368 Q26783879-8EEB58CE-18A9-457E-A41F-8B86D5893690 Q26825650-DD04BC37-6633-4704-8445-E087B02C6CB0 Q26864290-498CFEE8-50E4-45E0-B911-F883A7235930 Q26996425-3A1564DD-2FAE-4CB1-BCE8-E3FF22ED3891 Q27007529-C9435F16-C285-494D-A8C5-8A176E1E909E Q27024344-090F9D55-3825-4DE2-8380-DF76857C6CEB Q27681323-AD1CBF19-A24F-4F81-85DC-09C002F4B3E2 Q27687235-DEA7A34E-9B09-4F3A-B0BE-B5B14587D30D Q28475084-1D7BF6A3-7644-48D7-9D0F-42829EEAF461 Q28475743-17FFAD6B-E5A6-4E80-B411-0038DC06E813 Q28484081-28DE9051-D9F0-4CFC-AF5D-4C397B6EB1F5 Q28541281-0E6F66BF-4E01-4A30-BED0-0BBEB0671504 Q28731458-B5720799-9E5D-4558-9B12-8B2B546D7A46 Q28732752-8E93173B-35A6-420B-9A3E-F238C6FA57FD Q28740701-5D0BB1AA-3427-4654-9D2F-C12FC46A118F Q28740832-39F50010-5279-419B-B9B0-0319FBDA365C Q28741059-529C1F27-7A5C-4FB3-9091-5002C75A595E Q28741242-5E3785ED-7C42-4B61-A331-2785C4ACDF72 Q28742561-D22638B8-040A-47D4-AF0C-F5CC5FC4171E Q28743081-6033D472-A3FE-4E25-910A-E65830F054CA Q28744170-3F3BBEC0-EFF8-4751-B5BA-48E1E522D734 Q28744573-AAE287B2-7E03-4F09-93CD-D5F8DAC39546 Q28748331-8B2E2F43-5E2D-43EC-AAA0-D36283024E21 Q28748565-D45E5DDD-8ADB-4378-A868-F3242967B621 Q28749979-2E20D32B-9111-4D69-B2E6-0AFDD5E61A7B Q28750566-1BA374E4-24CE-48A6-9FDF-E630138338D5 Q30390904-8B228ADD-1711-4C98-A0AC-6620AA4C83BC Q30396940-8C9A84CE-412D-4C32-99CF-0B46314C3715 Q30484264-BE775CD6-3380-46F3-A5AD-ECEE42A9A190 Q30596414-191432A0-E5B7-4F3C-8AEA-3EA2CE691D50 Q30662529-B17B8C2C-F136-41A3-8EF1-B3121C3CF0C1 Q30788258-1558F5C6-27C5-496B-B302-D3A9DFCF609B Q30895708-3BB2B753-0EDB-4A5D-B67F-6922026ACDAB

P2860

Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age

http://www.wikidata.org/entity/Q24658073

description

2008 nî lūn-bûn

@nan

2008 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age

@ast

Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age

@en

Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age

@nl

type

label

Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age

@ast

Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age

@en

Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age

@nl

prefLabel

Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age

@ast

Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age

@en

Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age

@nl

P1433

Q24658073-7A6A5560-3882-46DF-A766-037559515BCB

P1476

Q24658073-B7101CB7-1B42-4A2A-9B8E-0DF882F6D622

P2093

Q24658073-0214AFE0-D9FD-450E-B743-CA682AECFA0D

Q24658073-05893086-E920-4A39-88D1-5EF997375B15

Q24658073-22EFB74D-B4D5-4E69-B6D8-724D4578E27A

Q24658073-24B4D454-49D3-44F7-A90D-6ECD691A2767

Q24658073-3D43A749-A467-4D7A-8B47-481EB8F33BE0

Q24658073-4104FAC4-A043-42DA-8628-0DFD72604A0F

Q24658073-42517D6B-1D86-4048-9758-B17D2AD3A717

Q24658073-5B861C0D-0399-4348-AC5A-FA0D0027D32B

Q24658073-5C86E9F2-EEC4-42D8-A22E-03262B9EAC26

Q24658073-9D0B20A3-7097-41C2-A5CF-0C67686FAC4A

P2860

Q24658073-0E3C17DA-DF2D-44E9-9300-483FF2CD97DB

Q24658073-168C75D7-883A-4C18-B457-79881CB52AB1

Q24658073-181AD758-846E-49CE-B97D-1D92327FEA1A

Q24658073-1AA2BB34-2B4C-49E4-8272-9D7546B788CB

Q24658073-2F6DB47E-5B08-49EA-8EAC-A95CCCCE0929

Q24658073-3D33C4DC-E936-4F6A-8EF5-F35D3DF0C288

Q24658073-49689688-B3C1-4616-9069-895ACEA57106

Q24658073-50C20115-1ED3-48B1-A347-F082A90DE086

Q24658073-55BBD197-226D-4718-9C30-4F4790C5B5FB

Q24658073-583AC36E-9110-425D-85DF-55BA13554592

P304

Q24658073-CCEFE5DD-AB09-4CA9-9178-706C671FA278

P31

Q24658073-1B72B133-354D-48E7-896E-EC9288CF02AE

P3181

Q24658073-B3520034-B1E9-42D2-B16C-4539F3EE184B

P356

Q24658073-A24FD531-1ABE-47DC-B1F6-9D1C7389EC4A

P407

Q24658073-C50C8373-3FB3-4FF3-90CA-B417A50D7AB7

P433

Q24658073-DEF81C27-90EB-4F2B-AB95-F9772A233918

P478

Q24658073-1E10AA5E-8341-4FD7-9942-9647A737CA2F

P50

Q24658073-0C2E7EA8-EDBF-469E-96DB-8BCAF526523A

Q24658073-1E19E686-8CBF-4A80-B887-A0A9268FF547

Q24658073-474FD1A3-DB20-4FDA-B60B-FE4C223736A5

Q24658073-961C541C-A391-4BF5-AF34-2551A578E59A

Q24658073-9DBE2CF7-1594-4017-85DA-2492E1CFDC78

Q24658073-B44A22E5-AF85-4402-8A8B-7DA746D32517

Q24658073-E17D81A7-7C80-4281-9285-603CE884FAC3

Q24658073-E51133E4-8D41-4CF6-B016-C562759DB66D

Q24658073-E8E5620B-0B2E-4592-8503-657DD13F797C

Q24658073-EC01A3B8-B574-4577-816C-54DB1BFDF0D3

P577

Q24658073-2FB5A598-F713-447C-A360-3195A1F06CE2

P698

Q24658073-92744DD7-FB7D-4112-9B69-237F5984D2AA

P921

Q24658073-BA91A4D4-AC41-49A2-B4AB-020C6F4CD57D

P932

Q24658073-26F668C7-B60E-431D-88D6-F37767F1407F

P3181

P356

P1433

The New England Journal of Medicine

P1476

Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age

@en

P2093

Ally Olotu

http://www.w3.org/2001/XMLSchema#string

Amanda Leach

http://www.w3.org/2001/XMLSchema#string

Anangisye Malabeja

http://www.w3.org/2001/XMLSchema#string

Barbara Savarese

http://www.w3.org/2001/XMLSchema#string

Jayne Gould

http://www.w3.org/2001/XMLSchema#string

Jean-Francois Stallaert

http://www.w3.org/2001/XMLSchema#string

Joe Cohen

http://www.w3.org/2001/XMLSchema#string

John Lusingu

http://www.w3.org/2001/XMLSchema#string

Ken O Awuondo

http://www.w3.org/2001/XMLSchema#string

Marc Lievens

http://www.w3.org/2001/XMLSchema#string

P2860

Insecticide-treated bed nets and curtains for preventing malaria

Impact of artemisinin-based combination therapy and insecticide-treated nets on malaria burden in Zanzibar

The global distribution of clinical episodes of Plasmodium falciparum malaria

Effect of artemether-lumefantrine policy and improved vector control on malaria burden in KwaZulu-Natal, South Africa

Malaria: progress, perils, and prospects for eradication

Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial

Estimating mortality, morbidity and disability due to malaria among Africa's non-pregnant population.

Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial.

The global distribution and population at risk of malaria: past, present, and future

GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives.

P304

2521-32

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2369296

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJMOA0807381

http://www.w3.org/2001/XMLSchema#string

P407

P433

24

http://www.w3.org/2001/XMLSchema#string

P478

359

http://www.w3.org/2001/XMLSchema#string

P50

Patricia Njuguna

Lorenz von Seidlein

Chris J Drakeley

Martha M Lemnge

P577

2008-12-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19064627

http://www.w3.org/2001/XMLSchema#string

P921

P932

2655100

http://www.w3.org/2001/XMLSchema#string